QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 25, 2007, 27(30):7899-7910; doi:10.1523/JNEUROSCI.1396-07.2007

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Tang, T.-S. Articles by Bezprozvanny, I. Search for Related Content PubMed PubMed Citation Articles by Tang, T.-S. Articles by Bezprozvanny, I.

 Previous Article  |  Next Article 

Neurobiology of Disease
Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease

Tie-Shan Tang, Xi Chen, Jing Liu, and Ilya Bezprozvanny

Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390

Correspondence should be addressed to Dr. Ilya Bezprozvanny at the above address. Email: ilya.bezprozvanny{at}utsouthwestern.edu

Huntington's disease (HD) is a neurodegenerative disorder caused by polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Htt^exp causes selective degeneration of striatal medium spiny neurons (MSNs) in HD patients. Striatal MSN neurons receive glutamatergic input from the cortex and dopaminergic input from the substantia nigra. In previous studies with the yeast artificial chromosome (YAC128) transgenic HD mouse model, we established a connection between glutamate receptor activation, disturbed calcium (Ca²⁺) signaling, and apoptosis of HD MSNs (Tang et al., 2005). Here, we used the same YAC128 mouse model to investigate the role of dopaminergic signaling in HD. We discovered that glutamate and dopamine signaling pathways act synergistically to induce elevated Ca²⁺ signals and to cause apoptosis of YAC128 MSNs in vitro. We demonstrated that potentiating effects of dopamine are mediated by D₁-class dopamine receptors (DARs) and not by D₂-class DARs. Consistent with in vitro findings, in whole-animal experiments we found that persistent elevation of striatal dopamine levels exacerbated the behavioral motor deficits and MSN neurodegeneration in YAC128 mice. We further discovered that the clinically relevant dopamine pathway inhibitor tetrabenazine alleviated the motor deficits and reduced striatal cell loss in YAC128 mice. Our results suggest that dopamine signaling pathway plays an important role in HD pathogenesis and that antagonists of dopamine pathway such as tetrabenazine or dopamine receptor blockers may have a therapeutic potential for treatment of HD beyond well established "symptomatic" benefit.

Key words: dopamine; calcium signaling; Huntington's disease; transgenic mouse; stereology; rotarod; tetrabenazine

---

Received April 7, 2005; revised June 1, 2007; accepted June 4, 2007.

Correspondence should be addressed to Dr. Ilya Bezprozvanny at the above address. Email: ilya.bezprozvanny{at}utsouthwestern.edu

This article has been cited by other articles:

				D. E. Ehrnhoefer, S. L. Butland, M. A. Pouladi, and M. R. Hayden Mouse models of Huntington disease: variations on a theme Dis. Model. Mech., March 1, 2009; 2(3-4): 123 - 129. [Abstract] [Full Text] [PDF]

				T.-S. Tang, C. Guo, H. Wang, X. Chen, and I. Bezprozvanny Neuroprotective Effects of Inositol 1,4,5-Trisphosphate Receptor C-Terminal Fragment in a Huntington's Disease Mouse Model J. Neurosci., February 4, 2009; 29(5): 1257 - 1266. [Abstract] [Full Text] [PDF]

				X. Chen, T.-S. Tang, H. Tu, O. Nelson, M. Pook, R. Hammer, N. Nukina, and I. Bezprozvanny Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3 J. Neurosci., November 26, 2008; 28(48): 12713 - 12724. [Abstract] [Full Text] [PDF]

				P. Paoletti, I. Vila, M. Rife, J. M. Lizcano, J. Alberch, and S. Gines Dopaminergic and Glutamatergic Signaling Crosstalk in Huntington's Disease Neurodegeneration: The Role of p25/Cyclin-Dependent Kinase 5 J. Neurosci., October 1, 2008; 28(40): 10090 - 10101. [Abstract] [Full Text] [PDF]

				H. Runne, E. Regulier, A. Kuhn, D. Zala, O. Gokce, V. Perrin, B. Sick, P. Aebischer, N. Deglon, and R. Luthi-Carter Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry J. Neurosci., September 24, 2008; 28(39): 9723 - 9731. [Abstract] [Full Text] [PDF]

				A. Benchoua, Y. Trioulier, E. Diguet, C. Malgorn, M.-C. Gaillard, N. Dufour, J.-M. Elalouf, S. Krajewski, P. Hantraye, N. Deglon, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II Hum. Mol. Genet., May 15, 2008; 17(10): 1446 - 1456. [Abstract] [Full Text] [PDF]

				L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, and X. Zhuang Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice J. Neurosci., January 9, 2008; 28(2): 425 - 433. [Abstract] [Full Text] [PDF]

				E. C. Stack, A. Dedeoglu, K. M. Smith, K. Cormier, J. K. Kubilus, M. Bogdanov, W. R. Matson, L. Yang, B. G. Jenkins, R. Luthi-Carter, et al. Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice J. Neurosci., November 21, 2007; 27(47): 12908 - 12915. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help